### [Background]
In the pharmaceutical and biotech industry, the reliability of disclosures is a key indicator for evaluating corporate value. In particular, disclosures related to research and development (R&D) performance significantly impact investors' decisions. Samchundang Pharm was once highly anticipated in the market for its innovative technology development and aggressive investment. However, the recent series of 'unconfirmed' disclosure controversies has quickly shattered this positive image. In the past, Samchundang Pharm continued its growth through aggressive R&D investment and overseas market expansion, but this incident raises fundamental questions about this growth strategy. Especially in the highly competitive pharmaceutical and biotech market, a decline in credibility is a matter of survival for the company, making the situation even more serious.
### [Current Situation]
As of April 2, 2026, local time, Samchundang Pharm is at the center of a controversy involving 23 'unconfirmed' disclosures. Specifically, these disclosures contain information that significantly affects investors' decision-making, such as clinical trial results, technology transfer agreements, and the progress of new drug development. The problem is that this information is disclosed in an 'unconfirmed' state, causing confusion among investors. Some investors are raising suspicions that Samchundang Pharm intentionally leaked uncertain information to inflate its stock price, and are even showing signs of collective legal action. What is even more serious is the news that Samchundang Pharm has reduced its R&D investment in the midst of this controversy. Although the specific reduction scale has not yet been disclosed, industry experts are concerned that this R&D investment reduction will seriously damage Samchundang Pharm's future growth engine. An analyst at a securities firm, who requested anonymity, predicted that "Samchundang Pharm's corporate value is likely to decline further due to the unconfirmed disclosure controversy and the reduction in R&D investment." In addition, according to an internal source at Samchundang Pharm, the morale of internal employees is declining due to this incident, and the possibility of key personnel leaving is also being raised.
### [In-depth Analysis]
Samchundang Pharm's 'unconfirmed' disclosure controversy is not just a matter of corporate credibility, but also adds to the seriousness in that it can lead to distrust in the entire capital market. Investors make investment decisions based on trust in the information provided by companies, and Samchundang Pharm's case can be seen as an act of undermining this basic trust. In particular, the pharmaceutical and biotech industry is a field that requires technical expertise, so general investors have no choice but to rely more on the information provided by companies. Therefore, 'unconfirmed' disclosures can deepen information asymmetry and cloud investors' rational judgment. In addition, this incident not only causes a drop in Samchundang Pharm's stock price, resulting in huge losses for investors, but can also adversely affect the management of partner companies. Furthermore, Samchundang Pharm's crisis cannot rule out the possibility of leading to a contraction in investment sentiment in the entire domestic pharmaceutical and biotech industry. Legal experts point out that Samchundang Pharm's 'unconfirmed' disclosure act may constitute a violation of the Capital Market Act, and are mentioning the possibility of a prosecution investigation. If it is revealed that Samchundang Pharm violated the Capital Market Act, management may be subject to criminal punishment, and the company's image is expected to be further damaged.
### [Future Prospects]
Samchundang Pharm is currently facing a serious crisis. The 'unconfirmed' disclosure controversy and R&D investment reduction are undermining the company's credibility and raising questions about its future growth potential. In order for Samchundang Pharm to overcome this crisis, it is most important to show a transparent and responsible management attitude. First of all, it must provide a clear explanation for the 'unconfirmed' disclosure controversy and resolve investors' misunderstandings. In addition, it should reconsider the decision to reduce R&D investment and strengthen efforts to secure future growth engines. Furthermore, it should improve corporate governance and strengthen the internal control system to prepare recurrence prevention measures. However, considering the current situation, it does not seem easy for Samchundang Pharm to restore trust and overcome the crisis in the short term. Investors should carefully monitor Samchundang Pharm's future actions and make investment decisions carefully. In particular, since Samchundang Pharm's stock price volatility is likely to increase, it is necessary to take full precautions in investment risk management. In the future, Samchundang Pharm must make every effort to restore investors' trust through enhanced transparency, increased R&D investment, and active communication. Otherwise, Samchundang Pharm may be shunned by the market and eventually disappear into history.
